How do COPD comorbidities affect ICU outcomes?
Authors Ongel EA, Karakurt Z, Salturk C, Takir HB, Burunsuzoglu B, Kargin F, Ekinci GH, Mocin O, Gungor G, Adiguzel N, Yilmaz A
Received 29 June 2014
Accepted for publication 18 August 2014
Published 17 October 2014 Volume 2014:9(1) Pages 1187—1196
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 4
Editor who approved publication: Dr Richard Russell
Esra Akkutuk Ongel, Zuhal Karakurt, Cuneyt Salturk, Huriye Berk Takir, Bunyamin Burunsuzoglu, Feyza Kargin, Gulbanu H Ekinci, Ozlem Mocin, Gokay Gungor, Nalan Adiguzel, Adnan Yilmaz
Respiratory Intensive Care Unit Clinic, Sureyyapasa Chest Diseases and Thoracic Surgery Teaching and Research Hospital, Istanbul, Turkey
Background and aim: Chronic obstructive pulmonary disease (COPD) patients with acute respiratory failure (ARF) frequently require admission to the intensive care unit (ICU) for application of mechanical ventilation (MV). We aimed to determine whether comorbidities and clinical variables present at ICU admission are predictive of ICU mortality.
Methods: A retrospective, observational cohort study was performed in a tertiary teaching hospital's respiratory ICU using data collected between January 2008 and December 2012. Previously diagnosed COPD patients who were admitted to the ICU with ARF were included. Patients' demographics, comorbidities, body mass index (BMI), ICU admission data, application of noninvasive and invasive MV (NIV and IMV, respectively), cause of ARF, length of ICU and hospital stay, and mortality were recorded from their files. Patients were grouped according to mortality (survival versus non-survival), and all the variables were compared between the two groups.
Results: During the study period, a total of 1,013 COPD patients (749 male) with a mean age (standard deviation) of 70±10 years met the inclusion criteria. Comorbidities of the non-survival group (female/male, 40/131) were significantly higher compared with the survival group (female/male, 224/618): arrhythmia (24% vs 11%), hypertension (42% vs 34%), coronary artery disease (28% vs 11%), and depression (7% vs 3%) (P<0.001, P<0.035, P<0.001, and P<0.007, respectively). Logistic regression revealed the following mortality risk factors: need of IMV, BMI <20 kg/m2, pneumonia, coronary artery disease, arrhythmia, hypertension, chronic hypoxia, and higher acute physiology and chronic health evaluation II (APACHE II) scores. The respective odds ratios, confidence intervals, and P-values for each of these were as follows: 27.7, 15.7–49.0, P<0.001; 6.6, 3.5–412.7, P<0.001; 5.1, 2.9–8.8, P<0.001; 2.9, 1.5–5.6, P<0.001; 2.7, 1.4–5.2, P<0.003; 2.6, 1.5–4.4, P<0.001; 2.2, 1.2–3.9, P<0.008; and 1.1, 1.03–1.11, P<0.001.
Conclusion: Patients with severe COPD and cardiac comorbidities and cachexia should be closely monitored in ICU due to their high risk of ICU mortality.
Keywords: comorbidity, chronic obstructive pulmonary disease, intensive care unit
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Readers of this article also read:
Pini L, Pinelli V, Modina D, Bezzi M, Tiberio L, Tantucci C
Published Date: 1 September 2014
Chung JW, Kong KA, Lee JH, Lee SJ, Ryu YJ, Chang JH
Published Date: 21 July 2014
Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease
Brockwell C, Ampikaipakan S, Sexton DW, Price D, Freeman D, Thomas M, Ali M, Wilson AM
Published Date: 9 July 2014
Marques C, Ferreira JMF, Andronescu E, Ficai D, Sonmez M, Ficai A
Published Date: 28 May 2014
Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa
Liu CH, Kao JH
Published Date: 25 April 2014
Indirect costs in chronic obstructive pulmonary disease: A review of the economic burden on employers and individuals in the United States
Patel JG, Nagar SP, Dalal AA
Published Date: 19 March 2014
Gagnon P, Guenette JA, Langer D, Laviolette L, Mainguy V, Maltais F, Ribeiro F, Saey D
Published Date: 15 February 2014
Australian intern pharmacists’ perceived preparedness for practice, and their expectations and experiences of the internship year and future career intentions
Mak VSL, March G, Clark A, Gilbert AL
Published Date: 26 November 2013
P-wave indices in patients with pulmonary emphysema: do P-terminal force and interatrial block have confounding effects?
Chhabra L, Chaubey VK, Kothagundla C, Bajaj R, Kaul S, Spodick DH
Published Date: 14 May 2013
A highly sensitive and selective viral protein detection method based on RNA oligonucleotide nanoparticle
Changhyun Roh, Ho-Young Lee, Sang-Eun Kim, et al
Published Date: 22 April 2010